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ROS1-rearranged non–small-cell lung cancer (NSCLC) is a unique molecular subtype of lung cancer. Similar to EGFR 
mutation and ALK rearrangement, ROS1 rearrangement is a 
key oncogenic driver in a subgroup of lung cancer.1 The deter-
mination of ROS1 rearrangement status is vitally important 
for clinical diagnosis and treatment options in lung cancer. 
A woman with lung adenocarcinoma harboring three variants 
of ROS1 fusions including a novel variant was reported here. 
This case report and relevant study were approved by the insti-
tutional review boards of the Shanghai Pulmonary Hospital.
A 61-year-old Chinese woman was admitted with a 
2-month history of cough and dyspnea. A chest computed 
tomography revealed a 3-cm right middle lobe mass with mul-
tiple bilateral pulmonary nodules, multiple mediastinal lymph 
nodes, right pleural effusion, and a small amount of pericar-
dial effusion (Figure 1A). Brain magnetic resonance imaging 
showed multiple brain metastases (Figure 1B). No metasta-
sis was observed by abdominal ultrasound examination. The 
patient had no smoking history, but long-time exposure to 
fumes emitted from cooking oils. She had no family history of 
malignant tumor. Physical examination revealed left supracla-
vicular lymph nodes. A biopsy of left supraclavicular lymph 
nodes revealed metastatic lung adenocarcinoma. Meanwhile, 
adenocarcinoma cells were detected in the pleural fluids. The 
patient was clinically diagnosed with stage IV lung adeno-
carcinoma, T4N3M1b, with Eastern Cooperative Oncology 
Group performance status of 1.
The biopsied specimen from this patient was tested for 
EGFR using amplification-refractory mutation system assay 
with AmoyDx EGFR 29 Mutations Detection Kit and was tested 
for ALK, ROS1, and RET status using  reverse-transcriptase 
polymerase chain reaction (RT-PCR) assay with AmoyDx 
EML4-ALK Fusion Gene Detection Kit, AmoyDx ROS1 
Fusion Gene Detection Kit, and AmoyDx KIF5B-RET Fusion 
Gene Detection Kit (Amoy Diagnostics, Xiamen, China). 
The ROS1 fusion variants screened by AmoyDx ROS1 Fusion 
Gene Detection Kit were seen in Table 1. The findings showed 
that the patient was negative for EGFR mutations, EML4-ALK 
fusions, and KIF5B-RET fusions and was positive for ROS1 
fusions. Of interest, the results of RT-PCR for ROS1 fusion 
showed that both tube 1 and tube 2 were positive. Next, elec-
trophoretic analyses of RT-PCR products in tube 1 and tube 2, 
respectively, on 1.5% agarose gel found two products (a long 
fragment and a short fragment) in tube 1 (Figure 1C) and only 
a product in tube 2. The long fragment product in tube 1 was 
validated as a novel variant of ROS1 fusions, CD74 exon 7 
fused to ROS1 exon 32, and the short fragment product in tube 
1 was SLC34A2 (exon 13 del);ROS1 (exon 32) by gel extrac-
tion and direct sequencing (Figure 1D, E). The product in tube 
2 was CD74 (exon 6);ROS1 (exon 34) (Figure 1F).
The patient was treated with pemetrexed plus cisplatin 
in the first-line treatment setting. After one cycle of this regi-
men, the patient discontinued chemotherapy for intolerable 
toxicity and then received best support care. In addition, the 
patient did not receive crizotinib due to economic reason.
DISCUSSION
In NSCLC, some molecular aberrations, including EGFR 
mutation, and ALK, ROS1, and RET fusions, are shown to be 
associated with specific clinical characteristics and treatment 
benefits from corresponding targeted therapy. Of them, ROS1 
fusions occur in about ~1% of NSCLC and more frequently in 
younger, nonsmoking patients with adenocarcinoma.1 A phase 
I trial has demonstrated that crizotinib has dramatic antitu-
mor activity in patients with ROS1-rearranged NSCLC, with 
a high objective response rate of 56%.2 Therefore, the identi-
fication of ROS1 fusion variants is important for personalized 
therapy in lung cancer.
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ROS1 rearrangement was first reported in lung ade-
nocarcinoma by Rikova et al.3 in 2007. Three variants of 
ROS1 fusions involving two fusion patterns, SLC34A2 (exon 
4);ROS1(exon 32), SLC34A2 (exon 4);ROS1(exon 34), and 
CD74 (exon 6);ROS1(exon 34), were identified in this study.3 
Since then, the tumorigenicity of these two ROS1 fusions was 
validated by tumor formation of 3T3 cells transduced with 
a retrovirus containing SLC34A2-ROS1 or CD74-ROS1 in 
immunocompromised nude mice.4,5 Up to now, a total of nine 
fusion partners of ROS1 including SLC34A2, CD74, tropomy-
osin 3 (TPM3), syndecan (SDC4), ezrin (EZR), leucine-rich 
repeats and immunoglobulin-like domains (LRIG3), fused in 
glioblastoma (FIG), endoplasmic reticulum protein retention 
receptor 2 (KDELR2), and coiled-coil domain containing 6 
(CCDC6) have been identified in NSCLC.1,6–11 Among them, 
CD74 and SLC34A2 are the most common fusion patterns of 
ROS1. All identified breakpoints of ROS1 are located in exon 
32, 34, or 35, which ensure that the resulting fusion genes har-
bor the kinase domain of ROS1.6 The first report of all known 
variants of ROS1 fusions were seen in Table 2. CD74(exon 
7);ROS1(exon 32) was first found as a ROS1 fusion variant in 
lung cancer in this case. Similar to CD74(exon 6);ROS1(exon 
32), CD74 exon 7 fused to ROS1 exon 32 allows the fusion 
gene to contain promoter of CD74 and the kinase domain as 
well as the transmembrane domain of ROS1. Therefore, we 
consider that CD74-ROS1(C7;R32) may have potential onco-
genic activity as a novel variant of ROS1 fusions. However, 
because of lack of DNA sequence of the fusion gene, we can-
not determine whether C7;R32 is a resulting variant from 
different genomic rearrangement or just a splice variant in 
mRNA of CD74-ROS1.
It was generally believed that oncogenic drivers were 
mutually exclusive in lung cancer.1,6,12 However, a concurrent 
occurrence of different oncogenic drivers has been described 
in rare cases.13–15 Rikova et al.3 found two variants of ROS1 
fusions, SLC34A2-ROS1 (S4;R32) and SLC34A2-ROS1 
(S4;R34), in a human NSCLC cell line (HCC78). We also iden-
tified that SLC34A2-ROS1 (S13del;R32) and SLC34A2-ROS1 
FIGURE 1.  Imaging examinations 
and molecular assays of the case. 
A, Chest computed tomography 
showed a 3-cm right middle lobe 
mass with multiple bilateral pul-
monary nodules. B, Brain magnetic 
resonance imaging showed brain 
metastasis. C, Electrophoretic imag-
ing of two products in the tube 1. D, 
CD74 exon 7 fused to ROS1 exon 32. 
E, SLC34A2 exon 13 (nucleotide posi-
tion 568) fused to ROS1 exon 32. F, 
CD74 exon 6 fused to ROS1 exon 34.
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(S13del;R34) coexisted in a female never-smoker with ade-
nocarcinoma in our previous study.16 In addition, Rimkunas 
et al.9 described two cases with adenocarcinoma harboring 
coexisting EGFR mutation and SLC34A2-ROS1 fusion. In this 
case, three variants of ROS1 fusions were identified concur-
rently. The above-mentioned findings suggested the possibil-
ity of coexistence of different ROS1 fusion variants with or 
without other somatic genetic alteration. Furthermore, recent 
studies have found that clonal evolution plays an important 
role in tumor progression and development of metastasis.17,18 
In this case, we first identified the coexistence of three variants 
involving two different fusion partners of ROS1 in a meta-
static lesion and validated all identified ROS1 fusion variants 
by sequencing. Based on reliable results, this finding may be 
explained by high heterogeneity in tumor tissue.
In addition, break-apart fluorescence in situ hybridiza-
tion (FISH) is the most commonly used diagnostic method for 
detecting ROS1 fusion genes to date. However, FISH cannot 
distinguish different variants of fusion genes using  break-apart 
probe. For this case, RT-PCR may be a more efficient diag-
nosis method than FISH because FISH cannot identify the 
coexistence of different variants of ROS1 fusions. Although 
there is no clinical evidence on potential difference in sensi-
tivity to ROS1 inhibitors among different variants with differ-
ent fusion partners of ROS1 to date, a difference in sensitivity 
to crizotinib in vitro between Ba/F3 cells transduced with 
SDC4-ROS1 and HCC78 cell harboring SLC34A2-ROS1 was 
described by Davies et al.7 The inhibition of crizotinib in Ba/
F3 cells transduced SDC4(exon 2);ROS1(exon 32) was more 
potent than in HCC78 cells that harbored SCL34A2-ROS1 
(IC
50
 values, 31 nmol/L versus 775 nmol/L) in their study.7 
Based on these preclinical data, we cannot exclude the possi-
bility that patients with NSCLC harboring difference variants 
of ROS1 fusions may have different response to ROS1 inhibi-
tors. Therefore, the diagnostic process for ROS1-rearranged 
lung cancer is worth further exploration.
CONCLUSION
The case report first described a novel variant of ROS1 fusions, 
CD74 exon 7 fused to ROS1 exon 32, in a female never-smoker 
with lung adenocarcinoma. Meanwhile, this case harbored 
three variants involving two different fusion partners of ROS1, 
CD74, and SLC34A2. For this patient, crizotinib may be an 
effective treatment. However, the mechanism and frequency 
of this phenomenon remain unclear. The possible difference 
in response to ROS1 inhibitors among patients harboring dif-
ferent ROS1 fusion variants needs to be further investigated.
TABLE 1.  The ROS1 Fusion Variants Detected by AmoyDx 
ROS1 Fusion Gene Detection Kit
Variant No.
Fusion Partners  
for ROS1, Exon ROS1 Exon Tube No.
1 SLC34A2, 4 32 1
2 SLC34A2, 13del2046 32 1
3 CD74, 6 32 1
4 SDC4, 2 32 1
5 SDC4, 4 32 1
6 SLC43A2, 4 34 2
7 SLC43A2, 13del2046 34 2
8 CD74, 6 34 2
9 SDC4, 4 34 2
10 EZR, 10 34 2
11 TMP3, 8 35 3
12 LRIG3, 16 35 3
13 GOPC, 8 35 3
14 GOPC, 4 36 4
TABLE 2.  The First Report of All Known Variants of ROS1 Fusion
Study Time of Publication Fusion Pattern
ROS1 Breakpoint 
(Exon)
Fusion Partner  
Breakpoint (Exon) Specimens
Rikova et al.3 December 2007 SLC34A2-ROS1 32 4 HCC78 cell line
34 4 HCC78 cell line
CD74-ROS1 34 6 NSCLC
Takeuchi et al.6 March 2012 SLC34A2-ROS1 32 13(del) NSCLC
34 13(del) NSCLC
CD74-ROS1 32 6 NSCLC
EZR-ROS1 34 10 NSCLC
LRIG3-ROS1 35 16 NSCLC
SDC-ROS1 32 2 NSCLC
32 4 NSCLC
34 4 NSCLC
TPM3-ROS1 35 8 NSCLC
Rimkunas et al.9 June 2012 FIG-ROS1 35 7 NSCLC
Govindan et al.10 September 2012 KDELR2-ROS1 Unknown Unknown NSCLC
Seo et al.11 September 2012 CCDC6-ROS1 6 34 NSCLC
Current report December 2013 CD74-ROS1 32 7 NSCLC
NSCLC, non–small-cell lung cancer.
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